Avacta's AVA6103 Shows Promising Preclinical Data in Pancreatic…

Event summary

Avacta presented FOCUS-01 trial design and preclinical data for AVA6103 at the AACR Conference on Pancreatic Cancer on September 25, 2026.
AVA6103 demonstrated durable complete and partial responses in PDAC mouse models using a dose-dense regimen.
High FAP expression in PDAC supports the mechanism of AVA6103's tumor-targeted delivery.
Initial clinical data from FOCUS-01 showed a favorable safety profile and proof of mechanism in patients.
First efficacy readout from the FOCUS-01 trial expected in H1 2027.

The big picture

Avacta's presentation at the AACR Conference underscores the potential of its pre|CISION® technology in targeting aggressive cancers like pancreatic ductal adenocarcinoma. The company's approach of using peptide-drug conjugates (PDCs) to enhance tumor-specific delivery of potent payloads positions it as a competitor in the evolving landscape of oncology treatments. The success of AVA6103 could validate Avacta's innovative platform and attract further investment in its pipeline.

What we're watching

Clinical Efficacy: Whether AVA6103 can sustain its preclinical efficacy in human trials, particularly in pancreatic cancer patients.
Regulatory Pathway: The pace at which Avacta can advance AVA6103 through clinical stages and secure regulatory approvals.
Competitive Positioning: How Avacta's pre|CISION® technology differentiates AVA6103 from existing ADCs like Enhertu® in the oncology market.